Literature DB >> 27445339

Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.

Roberta Cascella1, Claudia Capitini1, Giulia Fani1, Christopher M Dobson2, Cristina Cecchi1, Fabrizio Chiti3.   

Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin positive inclusions (FTLD-U) are two clinically distinct neurodegenerative conditions sharing a similar histopathology characterized by the nuclear clearance of TDP-43 and its associated deposition into cytoplasmic inclusions in different areas of the central nervous system. Given the concomitant occurrence of TDP-43 nuclear depletion and cytoplasmic accumulation, it has been proposed that TDP-43 proteinopathies originate from either a loss-of-function (LOF) mechanism, a gain-of-function (GOF) process, or both. We have addressed this issue by transfecting murine NSC34 and N2a cells with siRNA for endogenous murine TDP-43 and with human recombinant TDP-43 inclusion bodies (IBs). These two strategies allowed the depletion of nuclear TDP-43 and the accumulation of cytoplasmic TDP-43 aggregates to occur separately and independently. Endogenous and exogenous TDP-43 were monitored and quantified using both immunofluorescence and Western blotting analysis, and nuclear functional TDP-43 was measured by monitoring the sortilin 1 mRNA splicing activity. Various degrees of TDP-43 cytoplasmic accumulation and nuclear TDP-43 depletion were achieved and the resulting cellular viability was evaluated, leading to a quantitative global analysis on the relative effects of LOF and GOF on the overall cytotoxicity. These were found to be ∼55% and 45%, respectively, in both cell lines and using both readouts of cell toxicity, showing that these two mechanisms are likely to contribute apparently equally to the pathologies of ALS and FTLD-U.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Frontotemporal Dementia; Frontotemporal lobar degeneration; TAR DNA-binding protein 43 (TDP-43) (TARDBP); amyloid; amyotrophic lateral sclerosis (ALS) (Lou Gehrig disease); motor neuron disease; neurodegeneration; neurodegenerative disease; protein aggregation; protein misfolding

Mesh:

Substances:

Year:  2016        PMID: 27445339      PMCID: PMC5016682          DOI: 10.1074/jbc.M116.737726

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 2.  Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.

Authors:  Antonia Ratti; Emanuele Buratti
Journal:  J Neurochem       Date:  2016-06-15       Impact factor: 5.372

3.  Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor.

Authors:  Mercedes Prudencio; Karen R Jansen-West; Wing C Lee; Tania F Gendron; Yong-Jie Zhang; Ya-Fei Xu; Jennifer Gass; Cristiana Stuani; Caroline Stetler; Rosa Rademakers; Dennis W Dickson; Emanuele Buratti; Leonard Petrucelli
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

4.  Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro.

Authors:  Roberta Cascella; Simona Conti; Benedetta Mannini; Xinyi Li; Joel N Buxbaum; Bruno Tiribilli; Fabrizio Chiti; Cristina Cecchi
Journal:  Biochim Biophys Acta       Date:  2013-09-25

5.  TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.

Authors:  Hans Wils; Gernot Kleinberger; Jonathan Janssens; Sandra Pereson; Geert Joris; Ivy Cuijt; Veerle Smits; Chantal Ceuterick-de Groote; Christine Van Broeckhoven; Samir Kumar-Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-03       Impact factor: 11.205

6.  Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo.

Authors:  Edor Kabashi; Li Lin; Miranda L Tradewell; Patrick A Dion; Valérie Bercier; Patrick Bourgouin; Daniel Rochefort; Samar Bel Hadj; Heather D Durham; Christine Vande Velde; Guy A Rouleau; Pierre Drapeau
Journal:  Hum Mol Genet       Date:  2009-12-03       Impact factor: 6.150

7.  Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.

Authors:  Ian R A Mackenzie; Eileen H Bigio; Paul G Ince; Felix Geser; Manuela Neumann; Nigel J Cairns; Linda K Kwong; Mark S Forman; John Ravits; Heather Stewart; Andrew Eisen; Leo McClusky; Hans A Kretzschmar; Camelia M Monoranu; J Robin Highley; Janine Kirby; Teepu Siddique; Pamela J Shaw; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

8.  TDP-43 is a developmentally regulated protein essential for early embryonic development.

Authors:  Chantelle F Sephton; Shannon K Good; Stan Atkin; Colleen M Dewey; Paul Mayer; Joachim Herz; Gang Yu
Journal:  J Biol Chem       Date:  2009-12-29       Impact factor: 5.157

9.  Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.

Authors:  Lionel M Igaz; Linda K Kwong; Edward B Lee; Alice Chen-Plotkin; Eric Swanson; Travis Unger; Joe Malunda; Yan Xu; Matthew J Winton; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Clin Invest       Date:  2011-01-04       Impact factor: 14.808

10.  Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U.

Authors:  Kuen-Jer Tsai; Chun-Hung Yang; Yen-Hsin Fang; Kuan-Hung Cho; Wei-Lin Chien; Wei-Ting Wang; Tzu-Wei Wu; Ching-Po Lin; Wen-Mei Fu; Che-Kun James Shen
Journal:  J Exp Med       Date:  2010-07-26       Impact factor: 14.307

View more
  26 in total

1.  Cdc48/VCP and Endocytosis Regulate TDP-43 and FUS Toxicity and Turnover.

Authors:  Guangbo Liu; Aaron Byrd; Amanda N Warner; Fen Pei; Eman Basha; Allison Buchanan; J Ross Buchan
Journal:  Mol Cell Biol       Date:  2020-01-30       Impact factor: 4.272

2.  Mechanisms of Metabolite Amyloid Formation: Computational Studies for Drug Design against Metabolic Disorders.

Authors:  Massimiliano Meli; Hamutal Engel; Dana Laor; Ehud Gazit; Giorgio Colombo
Journal:  ACS Med Chem Lett       Date:  2019-02-15       Impact factor: 4.345

Review 3.  Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.

Authors:  Lindsey R Hayes; Petr Kalab
Journal:  Neurotherapeutics       Date:  2022-07-05       Impact factor: 6.088

Review 4.  TDP43 ribonucleoprotein granules: physiologic function to pathologic aggregates.

Authors:  Giulia Ada Corbet; Joshua R Wheeler; Roy Parker; Kaitlin Weskamp
Journal:  RNA Biol       Date:  2021-08-19       Impact factor: 4.766

Review 5.  Gene therapy for ALS: A review.

Authors:  Defne A Amado; Beverly L Davidson
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

6.  The N-terminal dimerization is required for TDP-43 splicing activity.

Authors:  Lei-Lei Jiang; Wei Xue; Jun-Ye Hong; Jun-Ting Zhang; Min-Jun Li; Shao-Ning Yu; Jian-Hua He; Hong-Yu Hu
Journal:  Sci Rep       Date:  2017-07-21       Impact factor: 4.379

Review 7.  RNA metabolism in neurodegenerative disease.

Authors:  Elaine Y Liu; Christopher P Cali; Edward B Lee
Journal:  Dis Model Mech       Date:  2017-05-01       Impact factor: 5.758

8.  TDP-43 aggregation mirrors TDP-43 knockdown, affecting the expression levels of a common set of proteins.

Authors:  S Prpar Mihevc; Marco Baralle; Emanuele Buratti; Boris Rogelj
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

9.  Platelet phosphorylated TDP-43: an exploratory study for a peripheral surrogate biomarker development for Alzheimer's disease.

Authors:  Rodger Wilhite; Jessica M Sage; Abdurrahman Bouzid; Tyler Primavera; Abdulbaki Agbas
Journal:  Future Sci OA       Date:  2017-08-16

10.  Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program.

Authors:  Ping Wang; Connor M Wander; Chao-Xing Yuan; Michael S Bereman; Todd J Cohen
Journal:  Nat Commun       Date:  2017-07-19       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.